Leerink Partners Maintains Outperform on Roivant Sciences, Raises Price Target to $32

Benzinga · 2d ago
Leerink Partners analyst David Risinger maintains Roivant Sciences (NASDAQ:ROIV) with a Outperform and raises the price target from $29 to $32.